Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2007 Oct 17;2007(4):CD003982.
doi: 10.1002/14651858.CD003982.pub2.

Azathioprine for multiple sclerosis

I Casetta  1 , G Iuliano, G Filippini
Affiliations
Meta-Analysis

Azathioprine for multiple sclerosis

I Casetta et al. Cochrane Database Syst Rev. .

Abstract

Background: Azathioprine is the most widely used immunosuppressive treatment in multiple sclerosis (MS). It is an alternative to interferon beta for treating MS also because it is less expensive. Concerns about its safety, mainly a possible increased risk of malignancy, has limited its use. This systematic review aimed to determine the trade off between the benefits and risks of azathioprine in multiple sclerosis.

Objectives: To compare azathioprine versus placebo. To determine the effect of azathioprine on major clinical outcomes, i.e., disability progression and relapses in patients with multiple sclerosis.

Search strategy: The Multiple Sclerosis Group's Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL- Issue 4, 2006), Cochrane Database of Systematic Reviews (CDSR - Issue 4, 2006), Database of Abstracts of Reviews of Effectiveness (DARE - searched 28.12.06) MEDLINE (PubMed) (1966 to December 2006), EMBASE (1980 to December 2006). Journals and reference lists were hand searched for relevant articles both to benefit and adverse effects. Regulatory agencies were additional sources of information for adverse effects.

Selection criteria: All parallel group randomised controlled trials (RCTs) comparing azathioprine treatment of a least one year duration with placebo for patients with multiple sclerosis. Cohorts, case controls, case series and case reports were also used to assess adverse effects.

Data collection and analysis: Potentially relevant references were evaluated and all data extracted by two independent authors.

Main results: The five trials that met our criteria included 698 randomised patients: data from 499 (71.5%) were available for analysis of relapse frequency in patients at one year's, from 488 (70%) at two years' and from 415 (59.5%) at three years' follow-up. Azathioprine reduced the number of patients who had relapses during the first year of treatment (relative risk reduction [RRR] =20%; 95% CI = 5% to 33%), at two years' (RRR =23%; 95% CI = 12% to 33%) and three years' (RRR =18%; 95% CI = 7% to 27%) follow-up. These results were consistent in sensitivity analysis. There was no heterogeneity among the studies. Data from only three small trials with a total of 87 patients were available to calculate the number of patients who progressed during the first two to three years. There was a statistically significant benefit (RRR = 42%; 95% CI = 7% to 64%) of azathioprine therapy at three years' follow-up; this result was robust after sensitivity analyses and there was no heterogeneity among the trials. Gastrointestinal disturbances, bone marrow suppression and hepatic toxicity were greater in the azathioprine group rather than in the placebo group; they were anticipated, and, by monitoring and dosage adjustment, were easily managed. Withdrawals due to adverse effects were few, occurring mostly during the first year of azathioprine treatment and mainly due to gastrointestinal intolerance (5%). Data from the trials and from cohort and case controls studies available in the literature did not show an increase in risk of malignancy from azathioprine. A possible long-term risk of cancer from azathioprine may be related to a treatment duration above ten years and cumulative doses above 600 g.

Authors' conclusions: Azathioprine is an appropriate maintenance treatment for patients with multiple sclerosis who frequently relapse and require steroids. Cumulative doses of 600 g should not be exceeded in relation to a possible increased risk of malignancy. Considering the trade off between the benefits and harms, azathioprine is a fair alternative to interferon beta for treating multiple sclerosis. A logical next step for future trials would seem the direct comparison of azathioprine and interferon beta. In fact the direct comparison between these two widely used treatments in multiple sclerosis has not been made.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

1
1
1.1
1.1. Analysis
Comparison 1 Azathioprine versus placebo, Outcome 1 Patients who had disability progression.
1.2
1.2. Analysis
Comparison 1 Azathioprine versus placebo, Outcome 2 Patients who had disability progression (worst).
1.3
1.3. Analysis
Comparison 1 Azathioprine versus placebo, Outcome 3 Change in EDSS disability score.
1.4
1.4. Analysis
Comparison 1 Azathioprine versus placebo, Outcome 4 Patients with at least one relapse.
1.5
1.5. Analysis
Comparison 1 Azathioprine versus placebo, Outcome 5 Patients with at least one relapse (worst).
1.6
1.6. Analysis
Comparison 1 Azathioprine versus placebo, Outcome 6 Mean number of relapses.
2.1
2.1. Analysis
Comparison 2 Azathioprine versus placebo, Outcome 1 Adverse effects.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

British & Dutch 1988 {published data only}
    1. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double‐masked trial of azathioprine in multiple sclerosis. Lancet 1988;2:179‐83. - PubMed
    1. The British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double‐blind controlled trial of azathioprine in the treatment of multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry 1987; Vol. 50:1387. - PMC - PubMed
Ellison 1989 {published data only}
    1. Ellison GW, Myers LW, Mickey ME, Graves MC, Tourtellotte WW, Syndulko, et al. A placebo‐controlled, randomized, double‐masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 1989;39:1018‐26. - PubMed
Ghezzi 1989 {published data only}
    1. Ghezzi A, Falco M, Locatelli C, et al. Clinical controlled randomized trial of azathioprine in multiple sclerosis. In: Consette RE, Delmotte P editor(s). Recent advances in multiple sclerosis therapy. Elsevier, 1989.
Goodkin 1991 {published data only}
    1. Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW. The efficacy of azathioprine in relapsing‐remitting multiple sclerosis. Neurology 1991;41:20‐5. - PubMed
Milanese 1993 {published data only}
    1. Milanese C, Mantia L, Salmaggi A, Eoli M. A double blind study on azathioprine efficacy in multiple sclerosis: final report. Journal of Neurology 1993;240:295‐8. - PubMed

References to studies excluded from this review

Aimard 1983 {published data only}
    1. Aimard G, Confavreux C, Ventre JJ, Guillot M, Devic M. Etude de 213 cas de sclerose en plaques traites par l' azathioprine de 1967‐ a 1982. Revue Neurologique 1983;139:509‐13. - PubMed
Cendrowski 1971 {published data only}
    1. Cendrowski WS. Therapeutic trial of azathioprine in MS. Acta Neurologica Scandinavica 1971;47:254‐60. - PubMed
Fratiglioni 1988 {published data only}
    1. Fratiglioni L, Siracusa GF, Amato MP, Sità D, Amaducci L. Effectiveness of azathioprine treatment in multiple sclerosis. Italian Journal of Neurological Sciences 1988;9:261‐4. - PubMed
Mertin 1980 {published data only}
    1. Mertin J, Rudge P, Knight SC, Thompson EJ, Healy MJR. Double‐blind controlled trial of immunosuppression in the treatment of Multiple Sclerosis. Lancet 1980;2:949‐51. - PubMed
Mertin 1982 {published data only}
    1. Mertin J, Rudge P, Kreemer R, Healey MJ, Knight SC, Compston A, et al. Double‐blind Controlled Trial of Immunosuppression in the Treatment of Multiple Sclerosis: Final Report. Lancet 1982;2:351‐4. - PubMed
Minderhoud 1988 {published data only}
    1. Minderhoud JM, Prange AJ, Luyckx GJ. A long‐term double‐blind controlled study on the effect of azathioprine in the treatment of multiple sclerosis. Clinical Neurology and Neurosurgery 1988;90:25‐8. - PubMed
Patzold 1982 {published data only}
    1. Patzold U, Hecker H, Pocklington P. Azathioprine in treatment of multiple sclerosis. Journal of the Neurological Sciences 1982;54:377‐94. - PubMed
    1. Patzold U, Pocklington P. Azathioprine in Multiple Sclerosis‐ A 3 year controlled study of its effectiveness. Journal of Neurology 1980;223:97‐117. - PubMed
Rosen 1979 {published data only}
    1. Rosen JA. Prolonged azathioprine treatment of non‐remitting muliptle sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 1979;42:338‐44. - PMC - PubMed
Silberberg 1973 {published data only}
    1. Silberberg D, Lisak R, Zwieman B. MS unaffected by azathioprine in pilot study. Archives of Neurology 1973;28:210‐12. - PubMed
Swinburn 1973 {published data only}
    1. * * Swinburn WR, Liversedge LA. Long‐term treatment of multiple sclerosis with azathioprine. Journal of Neurology, Neurosurgery and Psychiatry 1973;36:124‐6. - PMC - PubMed
Zeeberg 1985 {published data only}
    1. Zeeberg IE, Heltberg A, Fog T. Follow‐up evaluation after at least two years' treatment with azathioprine in a double‐blind trial. European Neurology 1985;24:435‐6.
Zeeberg 1986 {published data only}
    1. Zeeberg IE. Azathioprine Assessment in Progressive Multiple sclerosis. Clinical Aspects. In: Hommes OR editor(s). Multiple Sclerosis Research in Europe. Lanchaster, England: MTP, 1986:62‐70.

Additional references

ADRAC 2006
    1. The Australian Adverse Drug Reactions Bulletin. Drug induced pancreatitis. http://www.tga.gov.au/adr/aadrb/aadr0612.htm#a1 (access January 12 2007) 2006; Vol. 25, issue 6.
Amato 1993
    1. Amato MP, Pracucci G, Ponziani G, Siracusa G, Fratiglioni L, Amaducci L. Long‐term safety of azathioprine therapy in multiple sclerosis. Neurology 1993;43(4):831‐3. [MEDLINE: ] - PubMed
Anstey 2004
    1. Anstey AV, Wakelin S, Reynolds NJ, British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee. Guidelines for prescribing azathioprine in dermatology. British Journal of Dermatolology 2004;151(6):1123‐32. [MEDLINE: ] - PubMed
Confavreux 1996
    1. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case‐control study. Neurology 1996;46(6):1607‐12. - PubMed
Ebers 2006
    1. Ebers GC. Disease evolution in multiple sclerosis. Journal of Neurology 2006;253(Suppl 6):vi3‐8. [MEDLINE: ]
Elion 1993
    1. Elion GB. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Annals of New York Academy of Sciences 1993;685:400‐7. [MEDLINE: ] - PubMed
Higgins 2005
    1. Higgins JPT, Green S, editors. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 6. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd..
Hommes 2004
    1. Hommes OR, Weiner HL. Clinical practice of immunosuppressive treatments in MS: results of a second international questionnaire. Journal Neurological Science 2004;223:65‐7. - PubMed
Jones 1996
    1. M. Jones, D. Symmons, J. Finn, F. Wolfe. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. British Journal Rheumatology 1996;35(8):738‐45. - PubMed
Kinlen 1985
    1. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. American Journal Medicine 1985;78(1A):44‐9. [MEDLINE: ] - PubMed
Knipp 2005
    1. Knipp S, Hildebrandt B, Richter J, Haas R, Germing U, Gattermann N. Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica 2005;90(5):691‐3. [MEDLINE: ] - PubMed
Kremenchutzky 2006
    1. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006;129:584‐94. [MEDLINE: ] - PubMed
Kurtzke 1983
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444‐52. - PubMed
Lhermitte 1984
    1. Lhermitte F, Marteau R, Roullet E, Saxce H, Loridan M. Prolonged treatment of multiple sclerosis with average doses of azathioprine. An evaluation of 15 years' experience. Review Neurology (Paris) 1984;140(10):553‐8. [MEDLINE: ] - PubMed
Loke 2005
    1. Loke YK, Price D, Herxheimer A. Including adverse effects. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Appendix 6b. In: The Cochrane Library, Issue 3, 2005.
Lublin 1996
    1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiplosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907‐11. - PubMed
Massacesi 2005
    1. Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicano G, Konze A, et al. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Archives of Neurology 2005;62(12):1843‐7. - PubMed
Masunaga 2007
    1. Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H. Meta‐Analysis of Risk of Malignancy with Immunosuppressive Drugs in Inflammatory Bowel Disease. Annals Pharmacotherapy 2007;41(1):21‐8. [MEDLINE: ] - PubMed
McCabe 2003
    1. McCabe CJ, Chilcott J, Tappenden P, O'Hagan A, Claxton K, Abrams K, et al. Problems with the MS Risk sharing scheme. British Medical Journal 2003.
McEwan 1972
    1. McEwan A, Petty LG. Oncogenicity of immunosuppressive drugs. Lancet 1972;1(7745):326‐7. - PubMed
Palace 1997
    1. Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis. Lancet 1997;350:261. [MEDLINE: ] - PubMed
Patel 2006
    1. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. Journal of the American Academy of Dermatology 2006;55(3):369‐89. [MEDLINE: ] - PubMed
Poser 1983
    1. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals Neurology 1983;13:227‐31. - PubMed
Putzki 2006
    1. Putzki N, Knipp S, Ramczykowski T, Vago S, Germing U, Diener HC, et al. Secondary myelodysplastic syndrome following long‐term treatment with azathioprine in patients with multiple sclerosis. Multiple Sclerosis 2006;12(3):363‐6. [MEDLINE: ] - PubMed
Rosman 1973
    1. Rosman M, Bertino JR. Azathioprine. Annals of Internal Medicine 1973;79(5):694‐700. [MEDLINE: ] - PubMed
Rundles 1961
    1. Rundles RW, Laszlo J, Itoga T, Hobson JB, Garrison FE Jr. Clinical and hematologic study of 6[(1‐methyl‐4‐nitro‐5‐imidazolyl)thio]‐purine (B.W.57‐322) and related compounds. Cancer Chemotherapy Reports 1961;14:99‐115. [MEDLINE: ] - PubMed
Silman 1988
    1. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Annals Rheumatologic Diseases 1988;47(12):988‐92. [MEDLINE: ] - PMC - PubMed
Sudlow 2003
    1. Sudlow CL, Counsell CE. Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. British Medical Journal 2003;326(7385):388‐92. [MEDLINE: ] - PMC - PubMed
Taylor 2004
    1. Taylor L, Hughes RAC, McPherson K. The risk of cancer from azathioprine as a treatment of multiple sclerosis. European Journal of Neurology 2004;11(2):141‐2. [MEDLINE: ] - PubMed
Tiede 2003
    1. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28‐dependent Rac1 activation is the molecular target of azathioprine in primary human CD41 T lymphocytes. Journal Clinical Investigation 2003;111:1133‐45. - PMC - PubMed
Weinshenker 1989
    1. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133‐46. - PubMed
Willerding‐Mollmann
    1. Willerding‐Mollmann S, Wilkens L, Schlegelberger B, Kaiser U. Azathioprine‐associated myelodysplastic syndrome with cytogenetic aberrations. Deuttsch Medizinische Wochenschrift 2004;129(22):1246‐8. [MEDLINE: ] - PubMed
Yudkin 1991
    1. Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991;338(8774):1051‐5. [MEDLINE: ] - PubMed

MeSH terms